SiNtx Technologies Inc. (SINT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 10% of 52W Range • RSI-14 at 43.1 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While SINT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.79) and Max Pain ($1.81) forces dealer call-delta covering toward $4.68.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
SiNtx Technologies Inc. (SINT) slipped -1.15% to $1.72, trading at 10% of its 52-week range ($1.4 – $4.46). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
SALT LAKE CITY, Utah, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applic
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -64.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SINT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SINT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SiNtx Technologies Inc. (SINT) ranks #763 by composite RQD confidence (37/100, grade D-) and #870 by equity capitalization ($13.0M). Within this direct 5-issuer industry benchmark cohort, SINT leads on earnings valuation at N/A trailing P/E, while SINT leads on capital efficiency and profitability with -35.0% ROIC and 45.3% gross margin. GUTS currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with SINT at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SINT
ACTIVE
SiNtx Technologies Inc. | D- | 37/100 | — | 45.3% | -35.0% | -1.15% | $13.0M | Benchmark Subject |
| GUTS Fractyl Health Inc. | D+ | 52/100 | — | — | -35.0% | +11.40% | $13.2M | /guts-vs-sint → |
| CNSY Cerenome Inc. | D- | 36/100 | — | — | -35.0% | 0.00% | $13.2M | /cnsy-vs-sint → |
| CTSO Cytosorbents Corporation | E | 21/100 | — | 71.5% | -35.0% | -16.03% | $13.9M | /ctso-vs-sint → |
| ICU SeaStar Medical Holding Corporation | E | 33/100 | — | 95.7% | -35.0% | -6.85% | $12.2M | /icu-vs-sint → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SiNtx Technologies Inc. (SINT) reported GAAP revenue of $1.0M (-64.7% vs. FY2024 revenue of $2.9M , and -61.2% cumulative change since FY2023) , GAAP net income of -$10.4M, operating cash flow of -$8.6M, and free cash flow of -$8.8M (+6.2% YoY). On the balance sheet, SINT closed FY2025 with $9.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $1.0M | -$10.4M | -$8.6M | -$8.8M | $9.5M | — |
| FY2024 (FY) | 2024-12-31 | $2.9M | -$11.0M | -$8.6M | -$9.3M | $9.4M | — |
| FY2023 (FY) | 2023-12-31 | $2.6M | -$8.3M | -$14.1M | -$14.1M | — | — |
As of 2026-11-01, SiNtx Technologies Inc. (NASDAQ: SINT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.72 (-1.15% 1D, market cap $13.0M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SINT ranks #763 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), SINT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of 45.3%, and ROIC of -35.0%. By comparison, GUTS (Fractyl Health Inc.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M) and CNSY (Cerenome Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $13.2M). Among the 5-stock peer group, SINT leads on earnings multiple (N/A) while SINT leads on capital efficiency (-35.0% ROIC).
Per SINT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001269026), SiNtx Technologies Inc. generated $1.0M in revenue (-64.7% YoY), -$10.4M in net income, and -$8.8M in free cash flow against $9.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SINT last traded at $1.72 (-1.15% on volume of 9,469 shares), positioning the stock -3.91% below its 50-day simple moving average ($1.79) and -22.87% below its 200-day simple moving average ($2.23). Across its 52-week range of $1.40 to $4.46, SINT sits at the 10.5% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.51 to $1.93).
Why SINT Stock slipped -1.15% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.